Belotecan HCl
| Title | Journal |
|---|---|
| Durable response after just one cycle of belotecan-based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma. | The journal of obstetrics and gynaecology research 20140101 |
| Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120401 |
| Antitumor activity of CKD-602, a camptothecin derivative, in a mouse glioma model. | Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20120201 |
| Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer. | Cancer chemotherapy and pharmacology 20120101 |
| Allometric scaling of pegylated liposomal anticancer drugs. | Journal of pharmacokinetics and pharmacodynamics 20111001 |
| Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors. | Journal of liposome research 20110601 |
| Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer. | Cancer 20110515 |
| Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix. | Japanese journal of clinical oncology 20110501 |
| A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer. | Lung cancer (Amsterdam, Netherlands) 20110401 |
| Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models. | Journal of liposome research 20110301 |
| Toxicity study of a new camptothecin anti-cancer agent CKD-602 in dogs: 4-week continuous intravenous dose by infusion pump and 4-week repeated intravenous dose. | Regulatory toxicology and pharmacology : RTP 20101101 |
| Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial. | Lung cancer (Amsterdam, Netherlands) 20101001 |
| A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer. | Lung cancer (Amsterdam, Netherlands) 20100601 |
| Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer. | American journal of clinical oncology 20100601 |
| The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer. | Journal of chemotherapy (Florence, Italy) 20100601 |
| Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience. | The journal of obstetrics and gynaecology research 20100201 |
| Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer. | Cancer 20100101 |
| Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. | Clinical pharmacology and therapeutics 20091101 |
| Decreased urinary secretion of belotecan in folic acid-induced acute renal failure rats due to down-regulation of Oat1 and Bcrp. | Xenobiotica; the fate of foreign compounds in biological systems 20091001 |
| Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer. | Annals of the New York Academy of Sciences 20090801 |
| CKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell lines. | Oncology reports 20090601 |
| Apoptotic effect of CKD-602 (Camtobell) on oral squamous cell carcinoma cell lines. | Oral oncology 20090301 |
| Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090215 |
| Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. | Pharmaceutical research 20081101 |
| Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer. | Gynecologic oncology 20080601 |
| Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. | Annals of oncology : official journal of the European Society for Medical Oncology 20080101 |
| Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts. | Clinical cancer research : an official journal of the American Association for Cancer Research 20071201 |
| Effect of probenecid on the biliary excretion of belotecan. | Archives of pharmacal research 20071101 |
| A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20071015 |
| Reproductive toxicity evaluation of a new camptothecin anticancer agent, CKD-602, in pregnant/lactating female rats and their offspring. | Cancer chemotherapy and pharmacology 20070201 |
| STEALTH liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models. | Anticancer research 20070101 |
| Evaluation of the toxic potentials of a new camptothecin anticancer agent CKD-602 on fertility and early embryonic development in rats. | Regulatory toxicology and pharmacology : RTP 20060801 |
| 4-Week repeated intravenous dose toxicity study of a new camptothecin anticancer agent CKD-602 in dogs. | Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20050501 |
| Effects of CKD-602, a new camptothecin anticancer agent, on pregnant does and embryo-fetal development in rabbits. | Drug and chemical toxicology 20050101 |
| Embryotoxic effects of CKD-602, a new camptothecin anticancer agent, in rats. | Reproductive toxicology (Elmsford, N.Y.) 20050101 |
| Subacute toxicity evaluation of a new camptothecin anticancer agent CKD-602 administered by intravenous injection to rats. | Regulatory toxicology and pharmacology : RTP 20041201 |
| CKD-602. Chong Kun Dang. | Current opinion in investigational drugs (London, England : 2000) 20031201 |
| Simple and sensitive determination of the new antitumor drug CKD-602 in human plasma by liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030125 |
| Safety pharmacology of CKD-602, a novel anticancer agent. | Arzneimittel-Forschung 20030101 |
| In vitro pharmacodynamics of CKD-602 in HT-29 cells. | Archives of pharmacal research 20021001 |
| Preformulation studies of a novel camptothecin anticancer agent, CKD-602: physicochemical characterization and hydrolytic equilibrium kinetics. | International journal of pharmaceutics 20020604 |